Европейски съюз - чешки - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - přípravky proti dermatitidě, kromě kortikosteroidů - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

bb pharma a.s., praha array - 651 furosemid - injekční roztok - 10mg/ml - furosemid

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

bb pharma a.s., praha array - 651 furosemid - injekční roztok - 12,5mg/ml - furosemid

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 1593 ibuprofen - perorální suspenze - 20mg/ml - ibuprofen

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 1593 ibuprofen - perorální suspenze - 40mg/ml - ibuprofen

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

exelgyn, paris array - 9539 mifepriston - tableta - 200mg - mifepriston

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

exelgyn, paris array - 9539 mifepriston - tableta - 600mg - mifepriston

Европейски съюз - чешки - EMA (European Medicines Agency)

novo nordisk a/s - lidského inzulínu - diabetes mellitus - léky užívané při diabetu - léčba diabetes mellitus.

Европейски съюз - чешки - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekurzorová buněčná lymfoblastická leukémie-lymfom - antineoplastická činidla - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Европейски съюз - чешки - EMA (European Medicines Agency)

novo nordisk a/s - inzulín detemir - diabetes mellitus - léky užívané při diabetu - léčba diabetes mellitus u dospělých, dospívajících a dětí ve věku 1 roku a starší.